Displaying 211 - 220 of 243
Alternative Name: Tenofovir Disoproxil Fumarate (TDF) + Levonorgestrel Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Albert Einstein College of Medicine, NIAID, Northwestern University
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Testicular heat supplementation
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: University of California at Los Angeles
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Testicular
Developer: Parsemus Foundation, University of Bari, University of California, University of North Carolina at Chapel Hill
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Target
User: Male
Hormonal: No
Developer: Baylor College of Medicine, NICHD
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: TU; Aveed
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare, National Research Institute for Family Planning in Beijing
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: TV-46046
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Teva Branded Pharmaceutical Products R&D, Inc.
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Tenofovir (TFV) and levonorgestrel (LNG) ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: CONRAD
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: IUD HBCu375/MCu375 and TCu380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tianjin Medical Instrument Factory
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: RISUG in the Fallopian Tube
User: Female
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Fallopian Tube
Developer: Indian Institute of Technology, Kharagpur
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
Alternative Name: Triclovera; OSKB -1
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: PT. Tunggal Idaman Abdi
Development Stage: Marketed
Development Phase: Limited Market Availability

Pages

Displaying 1 - 10 of 70
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Adenylate Cyclase 10 and cyclic adenosine monophopshate, sAC and cAMP, soluble adenylyl cyclase
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Alternative Name: Mullerian-inhibiting Substance (MIS), Mullerian-inhibiting Hormone (MIH), Mullerian-inhibiting Factor (MIF), Mullerian Duct Inhibitory Factor (MDIF), Mullerian Regression Factor (MRF), Anti-paramesonephric Hormone (APH)
Development Stage: Lead Optimization
Alternative Name: Astacin Like Metalloendopeptidase, Ovastacin, Sperm Acrosomal SLLP1 Binding, SAS1B, Oocyte Astacin, EC 3.4
Target
User: Female
Hormonal: No
Development Stage: Target Validation

Pages

Displaying 21 - 30 of 121
Alternative Name: DVD2
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: FHI 360
Development Stage: Phase I
Alternative Name: DMAU
User: Male
Hormonal: Yes
Duration Type: Short-acting
Developer: BIOQUAL, Inc., NICHD, University of California at Los Angeles
Development Stage: Phase I
Alternative Name: Depot Medroxyprogesterone Acetate (DMPA) + Testosterone
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: ANZAC Research Institute
Development Stage: Phase I
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: National Research Institute for Family Planning in Beijing
Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: International Partnership for Microbicides, USAID
Development Stage: Phase I
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier, Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Viramal Limited
Development Stage: Pre-clinical
Alternative Name: Merck Vaginal Ring MK-8342B
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360, pH Sciences
Development Stage: Pre-clinical

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV